According to psychiatrist Russell Margolis, clinical director of the new Johns Hopkins Precision Medicine Center of Excellence for Schizoaffective Disorders, the goal of the center is to create individualized treatment plans for patients, based on the idea that the disorders can be divided into three subtypes:
- Those who will likely respond favorably to traditional antipsychotics
- Those who do respond to clozapine but do not respond to traditional antipsychotics
- Individuals who do not respond to any drugs at all (ultra treatment resistance)